Spots Global Cancer Trial Database for multiple myeloma and plasma cell neoplasm
Every month we try and update this database with for multiple myeloma and plasma cell neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00482495 | Multiple Myelom... | bevacizumab gene expression... protein express... laboratory biom... | 18 Years - | Mayo Clinic | |
| Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer | NCT00002742 | Chronic Myelopr... Infection Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | amphotericin B ... nystatin | 2 Years - | National Cancer Institute (NCI) | |
| Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00006890 | Multiple Myelom... | prednisone thalidomide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00564889 | Multiple Myelom... | cyclophosphamid... dexamethasone lenalidomide | 18 Years - | Mayo Clinic | |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | NCT00005987 | Multiple Myelom... | carmustine cyclophosphamid... dexamethasone etoposide filgrastim mitoxantrone hy... recombinant int... sargramostim bone marrow abl... peripheral bloo... radiation thera... | - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Interleukin-12 in Treating Patients With Multiple Myeloma | NCT00003149 | Multiple Myelom... | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide | NCT00899080 | Multiple Myelom... | gene expression... reverse transcr... immunoenzyme te... laboratory biom... platelet aggreg... | - 120 Years | Eastern Cooperative Oncology Group | |
| Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma | NCT00006219 | Multiple Myelom... | clarithromycin prasterone | 18 Years - | Mayo Clinic | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma | NCT00566098 | Multiple Myelom... | MILs Melphalan PCV13 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant | NCT00369291 | Germ Cell Tumor Leukemia Lymphoma Multiple Myelom... | keyhole limpet ... tetanus toxoid | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004165 | Multiple Myelom... | filgrastim melphalan peripheral bloo... | - | Northwestern University | |
| Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma | NCT00028886 | Multiple Myelom... | filgrastim recombinant int... cyclophosphamid... dexamethasone doxorubicin hyd... melphalan thalidomide vincristine sul... bone marrow abl... peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00478075 | Multiple Myelom... | bortezomib immunologic tec... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma | NCT00942422 | Multiple Myelom... Precancerous Co... | defined green t... gene expression... protein analysi... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00742404 | Multiple Myelom... | bortezomib dexamethasone pegylated lipos... protein analysi... immunologic tec... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma | NCT00008242 | Multiple Myelom... | dexamethasone doxorubicin hyd... thalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment | NCT00389701 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Beta Alethine in Treating Patients With Myeloma | NCT00006466 | Multiple Myelom... Precancerous Co... | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma | NCT00567229 | Multiple Myelom... | rituximab lenalidomide microarray anal... flow cytometry laboratory biom... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00568880 | Multiple Myelom... | bortezomib hydroxychloroqu... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma | NCT00335647 | Multiple Myelom... | fluphenazine hy... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | NCT00334932 | Multiple Myelom... | bortezomib melphalan pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00008229 | Multiple Myelom... | filgrastim melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders | NCT00258258 | Multiple Myelom... | paricalcitol zoledronic acid | 18 Years - | Roswell Park Cancer Institute | |
| Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma | NCT00014339 | Multiple Myelom... | Wobe-Mugos E melphalan prednisone quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma | NCT00004088 | Multiple Myelom... | filgrastim recombinant int... busulfan cyclophosphamid... melphalan pamidronate dis... thalidomide peripheral bloo... | - 65 Years | City of Hope Medical Center | |
| Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00445484 | Multiple Myelom... | pneumococcal po... lenalidomide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma | NCT00006013 | Multiple Myelom... | semaxanib | 18 Years - | Fox Chase Cancer Center | |
| Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00045136 | Multiple Myelom... | melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis | NCT00003853 | Multiple Myelom... | 4'-iodo-4'-deox... | 18 Years - | National Cancer Institute (NCI) | |
| AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00022282 | Multiple Myelom... | shark cartilage... | 18 Years - | AEterna Zentaris | |
| Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma | NCT00499577 | Multiple Myelom... | CMV pp65 peptid... hTERT I540/R572... pneumococcal po... survivin Sur1M2... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00477750 | Multiple Myelom... | lenalidomide melphalan prednisone | 18 Years - | Mayo Clinic | |
| Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00941720 | Multiple Myelom... | busulfan cyclophosphamid... autologous hema... | 18 Years - | Case Comprehensive Cancer Center | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| PS-341 in Treating Patients With Advanced Cancer | NCT00006362 | Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu... | bortezomib | 18 Years - | Mayo Clinic | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00941720 | Multiple Myelom... | busulfan cyclophosphamid... autologous hema... | 18 Years - | Case Comprehensive Cancer Center | |
| Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain | NCT00482378 | Multiple Myelom... Pain | Pamidronate Zoledronic acid Sm 153 lexidron... | 18 Years - 120 Years | Mayo Clinic | |
| Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure | NCT00416897 | Multiple Myelom... Renal Failure | chemotherapy dexamethasone plasmapheresis | 18 Years - | National Cancer Institute (NCI) | |
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma | NCT00942422 | Multiple Myelom... Precancerous Co... | defined green t... gene expression... protein analysi... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma | NCT00004072 | Multiple Myelom... | O6-benzylguanin... carmustine | - | Case Comprehensive Cancer Center | |
| Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | NCT00602706 | Multiple Myelom... | sargramostim melphalan autologous hema... peripheral bloo... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00477750 | Multiple Myelom... | lenalidomide melphalan prednisone | 18 Years - | Mayo Clinic | |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00008229 | Multiple Myelom... | filgrastim melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma | NCT00049673 | Multiple Myelom... | prednisone thalidomide | 16 Years - | Canadian Cancer Trials Group | |
| Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004158 | Multiple Myelom... | melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00687674 | Multiple Myelom... | dexamethasone sorafenib tosyl... Lenalidomide | 18 Years - 120 Years | Mayo Clinic | |
| Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma | NCT00897910 | Multiple Myelom... | flow cytometry immunoenzyme te... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00017602 | Multiple Myelom... | oblimersen sodi... dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00609167 | Multiple Myelom... | bortezomib cyclophosphamid... dexamethasone | 18 Years - | Mayo Clinic | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma | NCT00432458 | Multiple Myelom... | Thalidomide zoledronic acid | 18 Years - | Mayo Clinic | |
| Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant | NCT00469820 | Leukemia Multiple Myelom... | autologous tumo... peripheral bloo... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia | NCT00004181 | Chronic Myelopr... Leukemia Multiple Myelom... | busulfan cyclophosphamid... allogeneic bone... radiation thera... | 15 Years - 55 Years | Northwestern University | |
| Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma | NCT00006021 | Multiple Myelom... | ascorbic acid arsenic trioxid... | 18 Years - 120 Years | University of Miami | |
| Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00227682 | Multiple Myelom... | ascorbic acid arsenic trioxid... dexamethasone thalidomide | 18 Years - | OHSU Knight Cancer Institute | |
| Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant | NCT00288028 | Multiple Myelom... | bortezomib | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment | NCT00389701 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders | NCT00258258 | Multiple Myelom... | paricalcitol zoledronic acid | 18 Years - | Roswell Park Cancer Institute | |
| Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma | NCT00084747 | Multiple Myelom... | bortezomib | 18 Years - 69 Years | Jonsson Comprehensive Cancer Center | |
| Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma | NCT00432458 | Multiple Myelom... | Thalidomide zoledronic acid | 18 Years - | Mayo Clinic | |
| Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma | NCT00317798 | Drug/Agent Toxi... Multiple Myelom... | anti-thymocyte ... sirolimus | 18 Years - | University of Rochester | |
| Combination Chemotherapy in Treating Patients With Multiple Myeloma | NCT00002678 | Multiple Myelom... | dexamethasone melphalan prednisone | 18 Years - 120 Years | Canadian Cancer Trials Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
